Austin Chen is the Senior Vice President & Head of Research at Pipeline Therapeutics. Prior to joining Pipeline, Austin was an executive director at Inception Sciences where he and his team, often in partnership with external pharma partners, designed and synthesized compounds to address unmet medical needs in the field of oncology, ophthalmology, autoimmune diseases, infectious diseases, and neurodegenerative diseases. Five of these programs have since been acquired or successfully spun-out. Prior to that, Austin began his medicinal chemistry career at Merck Frosst Research Laboratories, where he contributed to the delivery of four compounds (MK-8141, MK-1594, MK-6478, MK-8831) into clinical development. Austin received his doctorate degree under the supervision of Professor Cathleen Crudden (Queen’s University, Institute of Transformative Biomolecules in Nagoya) and conducted post-doctoral research in the laboratory of Professor Matthew Shair (Harvard University). In his spare time, Austin enjoys spending time with his beautiful wife Karen and learning new tricks from his dog Ellie. Austin loves the Red Sox, obsesses with the Patriots, and engages in an occasional (but ultimately unfulfilling) fling with the Habs.